DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: BI 1015550

First Posted Date: 2024-05-10

Last Posted Date: 2024-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT06408870

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550 Formulation C2
Drug: BI 1015550 Formulation C1

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT06393127

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Phase 3

Withdrawn

Conditions: Myxofibrosarcoma (MFS)
Advanced Soft Tissue Sarcoma
Undifferentiated Pleomorphic Sarcoma (UPS)

Interventions: Drug: Ezabenlimab
Drug: Brigimadlin
Drug: Gemcitabine
Drug: Docetaxel

First Posted Date: 2024-04-17

Last Posted Date: 2024-07-17

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT06370871

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: repaglinide
Drug: midazolam
Drug: bupropion

First Posted Date: 2024-04-16

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT06367153

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zongertinib

First Posted Date: 2024-04-11

Last Posted Date: 2024-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT06360081

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Phase 2

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: BI 1839100

First Posted Date: 2024-04-11

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 230

Registration Number: NCT06360094

Locations: 🇧🇷
Hospital das Clinicas da FMUSP, São Paulo, Brazil
🇨🇦
Gordon & Leslie Diamond Health Care Centre (UBC), Vancouver, British Columbia, Canada
🇨🇦
St. Paul's Hospital (Vancouver), Vancouver, British Columbia, Canada

and more 177 locations

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BI 456906
Drug: BI 1820237
Drug: Placebo for BI 1820237
Drug: Placebo for BI 456906

First Posted Date: 2024-04-08

Last Posted Date: 2025-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT06352424

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Phase 1

Recruiting

Conditions: Renal Impairment
Healthy

Interventions: Drug: BI 456906

First Posted Date: 2024-04-08

Last Posted Date: 2025-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT06352411

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: BI 3034701
Drug: Placebo matching BI 3034701

First Posted Date: 2024-04-08

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 125

Registration Number: NCT06352437

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Active, not recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo matching BI 1819479
Drug: BI 1819479

First Posted Date: 2024-03-28

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 319

Registration Number: NCT06335303

Locations: 🇦🇷
CEDIC - Centro de Investigacion Clinica, Caba, Argentina
🇦🇷
Centro de Investigación Clinica Belgrano, Caba, Argentina
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 161 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy